Research output per year
Research output per year
Personal profile
Biography
Dr. Ole Tietz is a Research Fellow at the Dementia Research Centre of the Faculty of Medicine and Health Sciences at Macquarie University. Ole graduated from Imperial College London, UK, and completed his PhD at the University of Alberta, Canada, in 2015. His thesis dealt with the imaging of inflammation using radiotracers directed against cyclooxygenase-2 and was supervised by Prof. Frank Wuest. This was followed by post-doctoral fellowships at the University of Cambridge, where he developed imaging agents for early markers of neurodegeneration, and the University of Oxford, where he worked on technologies for transporting antibodies into cells. Ole is a member of the drug development group and works on developing antibodies for the treatment of dementia.
Research interests
Ole is interested in developing novel drugs against intracellular molecular targets for diagnosis and therapy of neurodegenerative diseases. This includes the rational design of small molecules and their optimization for cellular entry; the design and study of novel cell penetrating peptide complexes for the transport of exogenous cargo into cells; and the engineering and modification of antibodies to affect their endosomal escape and target engagement in the cytosol and nucleus.
Education/Academic qualification
Oncology, PhD, University of Alberta
6 Jan 2011 → 18 Nov 2015
Award Date: 18 Nov 2015
Biomedical Physical Chemistry, MRes, Imperial College London
5 Oct 2008 → 15 Dec 2009
Award Date: 12 Oct 2010
Chemistry, BSc
3 Oct 2005 → 25 Jun 2008
Award Date: 14 Oct 2008
Fingerprint
Dive into the research topics where Ole Tietz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research Outputs
- 138 Citations
- 7 h-Index
- 14 Article
-
A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein
Zhao, Y., Tietz, O., Kuan, W. L., Haji-Dheere, A. K., Thompson, S., Vallin, B., Ronchi, E., Tóth, G., Klenerman, D. & Aigbirhio, F. I., 14 May 2020, In: Chemical Science. 11, 18, p. 4773-4778 6 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)2 Downloads (Pure) -
Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson’s disease
Kuan, W-L., Stott, K., He, X., Wood, T. C., Yang, S., Kwok, J. C. F., Hall, K., Zhao, Y., Tietz, O., Aigbirhio, F. I., Vernon, A. C. & Barker, R. A., 1 Feb 2021, In: Molecular Psychiatry. 26, 2, p. 556-567 12 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile7 Citations (Scopus)5 Downloads (Pure) -
PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model
Tietz, O., Wuest, M., Marshall, A., Glubrecht, D., Hamann, I., Wang, M., Bergman, C., Way, J. D. & Wuest, F., 26 Apr 2016, In: EJNMMI Research. 6, 1, p. 1-11 11 p., 37.Research output: Contribution to journal › Article › peer-review
Open AccessFile28 Citations (Scopus) -
Impact of structural alterations on the radiopharmacological profile of 18F-labeled pyrimidines as cyclooxygenase-2 (COX-2) imaging agents
Tietz, O., Marshall, A., Bergman, C., Wuest, M. & Wuest, F., 1 Jul 2018, In: Nuclear Medicine and Biology. 62-63, p. 9-17 9 p.Research output: Contribution to journal › Article › peer-review
4 Citations (Scopus) -
VCAM-1 targeted alpha-particle therapy for early brain metastases
Corroyer-Dulmont, A., Valable, S., Falzone, N., Frelin-Labalme, A. M., Tietz, O., Toutain, J., Soto, M. S., Divoux, D., Chazalviel, L., Pérès, E. A., Sibson, N. R., Vallis, K. A. & Bernaudin, M., 5 Mar 2020, In: Neuro-Oncology. 22, 3, p. 357-368 12 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Citations (Scopus)7 Downloads (Pure)